ELPIDA® (elsulfavirin), a new generation non-nucleoside reverse transcriptase inhibitor (NNRTI) and the first original Russian drug in the 21st century for the treatment of HIV infection, was registered in Russia.
The drug was developed by Viriom, a company at ChemRar High-Tech Center, in partnership with F. Hoffmann-La Roche (Switzerland) and with the support of the Russian Ministry of Industry and Trade provided under the Federal Target-Oriented Program “Development of Pharmaceutical and Medical Industry of the Russian Federation for the Period up to 2020 and Beyond.”
The multi-center Russian comparative study of ELPIDA® conducted in 12 clinical centers and 10 regions of Russia demonstrated high virological and immunological efficacy of the drug, which does not depend on the baseline viral load; high level of drug safety compared to other NNRTIs; and high genetic barrier for the development of resistance. The obtained data allowed the researchers to recommend ELPIDA® as a first-line treatment for HIV infection in combination antiretroviral therapy.
The full manufacturing cycle of the drug, including the pharmaceutical substance, is implemented in JSC IIHR of ChemRar Group.